Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. SDC1 (CD138) and GPRC5D mRNA expression.
  • Fig. S2. Correlation of higher GPRC5D expression by MM cells with shorter progression-free survival.
  • Fig. S3. GPRC5D protein expression on control cells.
  • Fig. S4. Representative flow cytometric analyses of antigen-independent and antigen-specific activation using the Jurkat Nur77-RFP reporter line.
  • Fig. S5. GPRC5D(109) CAR T cell–mediated cytotoxicity of MM cell lines with varying GPRC5D expression.
  • Fig. S6. Lysis of primary bone marrow aspirate MM cells by GPRC5D-targeted CAR T cells.
  • Fig. S7. Cytokine secretion by GPRC5D-targeted CAR T cells upon coculture with GPRC5D-expressing cells.
  • Fig. S8. Requirement of GPRC5D expression for activation through GPRC5D(109) CAR.
  • Fig. S9. Comparable surface expression of different CAR vectors on primary T cells.
  • Fig. S10. In vivo expansion and antitumor activity of GPRC5D-targeted CAR T cells in an RPMI-8226 MM xenograft model.
  • Fig. S11. Eradication of OPM2BCMA-KO MM cells by GPRC5D-targeted CAR T cells.
  • Fig. S12. Minimal cytokine release by GPRC5D-targeted CAR T cells upon coculture with primary human cell types isolated from normal tissues.
  • Fig. S13. Screening for murine and cynomolgus cross-reactive scFv clones.
  • Fig. S14. Schematic of the NHP study protocol.
  • Fig. S15. Viability and functionality of cynomolgus GPRC5D(108) CAR T cells.
  • Table S1. GPRC5D expression in normal tissue.
  • Table S2. Single chromogenic immunostaining conditions.
  • Table S3. Antibodies and reagents for IHC and RNA-ISH.
  • Table S4. Multiplex immunostaining conditions.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

More From Science Translational Medicine